A. Brian Jones
12Patents
5h-index
36Co-inventors
62Inventor score
Filing activity: Oct 28, 1996 → Jan 18, 2006
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5719296A | Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins | Human Necessities | 55 | Expired |
| US6569879B2 | Aryloxyacetic acids for diabetes and lipid disorders | Human Necessities | 40 | Expired |
| US7125865B2 | Therapeutic compounds for treating dyslipidemic conditions | Chemistry; Metallurgy | 19 | Expired |
| US6852738B2 | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders | Mechanical Engineering; Lighting; Heating | 12 | Expired |
| US6908934B2 | Therapeutic compounds for treating dyslipidemic conditions | Human Necessities | 10 | Expired |
| US5817757A | Inhibitors of peptide binding to MHO class II proteins | Emerging Cross-Sectional Technologies | 5 | Expired |
| US5840835A | Inhibitors of peptide binding to MHC class II proteins | Emerging Cross-Sectional Technologies | 3 | Expired |
| US7442701B2 | Amino-heterocycles as VR-1 antagonists for treating pain | Chemistry; Metallurgy | 3 | Expired |
| US7091230B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | Chemistry; Metallurgy | 1 | Expired |
| US7285563B2 | Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain | Chemistry; Metallurgy | 1 | Expired |
| US7329659B2 | Substituted-1-phthalazinamines as vr-1 antagonists | Chemistry; Metallurgy | 0 | Expired |
| US7495020B2 | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.